Introduction: Preclinical research suggests a role of Glucagon Like Peptide-1 Receptors (GLP-1R) on the regulation of human bronchial tone. We investigated the effect of GLP-1R agonists on lung function of Type 2 Diabetes Mellitus (T2DM) population without co-existing chronic obstructive respiratory disorders.Methods: This was a prospective cohort study that examined change in lung function measurements over two years of T2DM patients (n= 32) treated with metformin monotherapy (control cohort), metformin plus GLP-1R agonists (GLP-1R agonists cohort), or metformin plus insulin (insulin cohort).Results: After 24 months of treatment, the forced expiratory volume in 1 s (FEV1) significantly (p < 0.05) increased from baseline in the GLP-1R agonists cohort (218 ml [95% CI 88-246]), but not in the control and insulin cohorts (94 ml [95% CI -28 -216] and 26 ml [95% CI -174 -226], respectively; p > 0.05 vs. baseline). The average increase in FEV1 in the GLP-1R agonists cohort was significantly greater than that in the control and insulin cohorts (delta: 110 ml [95% CI 18-202] and 177 ml [95% CI 85-270], respectively, p < 0.05). The forced vital capacity (FVC) also increased significantly more in the GLP-1R agonists cohort than in the control and insulin cohorts (overall delta FVC: 183 ml [95% CI 72-295], p < 0.05). The maximal expiratory flow at 50-75% significantly (p < 0.05) improved from baseline in the GLP-1R agonists cohort, but not in the control and insulin cohorts (p > 0.05).Conclusion: Our preliminary results suggest a potential new therapeutic perspective to treat airway disorders with GLP-1R agonists.

Rogliani, P., Matera, M.g., Calzetta, L., Hanania, N.a., Page, C., Rossi, I., et al. (2019). Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. RESPIRATORY MEDICINE, 154, 86-92 [10.1016/j.rmed.2019.06.015].

Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients

Rogliani P.;Calzetta L.;Galli A.;Cazzola M.;Lauro D.
2019-01-01

Abstract

Introduction: Preclinical research suggests a role of Glucagon Like Peptide-1 Receptors (GLP-1R) on the regulation of human bronchial tone. We investigated the effect of GLP-1R agonists on lung function of Type 2 Diabetes Mellitus (T2DM) population without co-existing chronic obstructive respiratory disorders.Methods: This was a prospective cohort study that examined change in lung function measurements over two years of T2DM patients (n= 32) treated with metformin monotherapy (control cohort), metformin plus GLP-1R agonists (GLP-1R agonists cohort), or metformin plus insulin (insulin cohort).Results: After 24 months of treatment, the forced expiratory volume in 1 s (FEV1) significantly (p < 0.05) increased from baseline in the GLP-1R agonists cohort (218 ml [95% CI 88-246]), but not in the control and insulin cohorts (94 ml [95% CI -28 -216] and 26 ml [95% CI -174 -226], respectively; p > 0.05 vs. baseline). The average increase in FEV1 in the GLP-1R agonists cohort was significantly greater than that in the control and insulin cohorts (delta: 110 ml [95% CI 18-202] and 177 ml [95% CI 85-270], respectively, p < 0.05). The forced vital capacity (FVC) also increased significantly more in the GLP-1R agonists cohort than in the control and insulin cohorts (overall delta FVC: 183 ml [95% CI 72-295], p < 0.05). The maximal expiratory flow at 50-75% significantly (p < 0.05) improved from baseline in the GLP-1R agonists cohort, but not in the control and insulin cohorts (p > 0.05).Conclusion: Our preliminary results suggest a potential new therapeutic perspective to treat airway disorders with GLP-1R agonists.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO
Settore MED/13 - ENDOCRINOLOGIA
English
Con Impact Factor ISI
Airway smooth muscle; Glucagon like Peptide-1 receptors; Lung function; Type 2 diabetes mellitus
Rogliani, P., Matera, M.g., Calzetta, L., Hanania, N.a., Page, C., Rossi, I., et al. (2019). Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. RESPIRATORY MEDICINE, 154, 86-92 [10.1016/j.rmed.2019.06.015].
Rogliani, P; Matera, Mg; Calzetta, L; Hanania, Na; Page, C; Rossi, I; Andreadi, A; Galli, A; Coppola, A; Cazzola, M; Lauro, D
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/217804
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 31
social impact